Allied (Allied) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Allied Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Allied is: No Data: Cannot be evaluated.

Competitive Comparison of Allied's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allied's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Allied's Risk Assessment falls into.

Allied (OTCPK:ALID) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Allied Risk Assessment Related Terms

Thank you for viewing the detailed overview of Allied's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Allied (Allied) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Corp (OTCPK:ALID) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1405 St. Paul Street, Suite 201, Kelowna, BC, CAN, V1Y 9N2

Website

https://www.allied.health

Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised ofsales ofcannabis products.

Executives

James George Robinson	director, 10 percent owner	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Anthony Zelen	director, 10 percent owner	1406 MINE HILL LANE, KELOWNA A1 V1P 1S5
Calum Hughes	director, 10 percent owner, officer: Chief Executive Officer	1847 CROSSGLEN COURT, KELOWNA A1 V1V 1S4
David Weinkauf	director, 10 percent owner, officer: Chief Business Development Off	192 SIERRA MORENA LANDING, SW CALGARY A0 T3H 4K4
Paul James Bullock	director, 10 percent owner, officer: Chief Operating Officer	1400 ST PAUL ST, SUITE 201, KELOWNA Z4 V1Y9N2